Abstract
Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed.
MeSH terms
-
Animals
-
Anti-Obesity Agents / adverse effects
-
Anti-Obesity Agents / metabolism
-
Anti-Obesity Agents / pharmacokinetics
-
Anti-Obesity Agents / therapeutic use*
-
Anti-Obesity Agents / toxicity
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Contraindications
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Hexoses / adverse effects
-
Hexoses / metabolism
-
Hexoses / pharmacokinetics
-
Hexoses / therapeutic use*
-
Hexoses / toxicity
-
Humans
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / metabolism
-
Hypoglycemic Agents / pharmacokinetics
-
Hypoglycemic Agents / therapeutic use*
-
Hypoglycemic Agents / toxicity
-
Obesity / drug therapy*
-
Structure-Activity Relationship
Substances
-
Anti-Obesity Agents
-
Hexoses
-
Hypoglycemic Agents
-
tagatose